UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K/A
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
May 15, 2015
PLASMATECH BIOPHARMACEUTICALS, INC.
(Exact name of registrant as specified in
its charter)
Delaware |
0-9314 |
83-0221517 |
(State or other jurisdiction of
incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
4848 Lemmon Avenue, Suite 517, Dallas, TX |
|
75219 |
(Address of principal executive offices) |
|
(Zip Code) |
(214) 905-5100
(Registrant’s telephone number, including
area code)
PLASMATECH BIOPHARMACEUTICALS, INC.
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Explanatory Note
PlasmaTech Biopharmaceuticals, Inc (“PlasmaTech”)
filed a Current Report on Form 8-K with the Securities and Exchange Commission (the “SEC”) on May 18, 2015 (the “Initial
Filing”) to report, among other things, the completion of PlasmaTech’s acquisition of Abeona Therapeutics LLC (“Abeona”),
an Ohio limited liability corporation.
This Form 8-K/A is being filed solely to
amend and supplement Item 9.01 of the Initial Filing to include Abeona’s financial statements and pro forma financial information
required by Item 9.01 of Form 8-K, which were not previously filed with the Initial Filing and are permitted to be filed by amendment
no later than 71 calendar days after the Initial Filing was required to be filed with the SEC. This Form 8-K/A amends the Initial
Filing for the inclusion of the foregoing financial statements and pro forma consolidated financial statements and does not amend
or modify the Initial Filing in any other respect.
ITEM 9.01 FINANCIAL
STATEMENTS AND EXHIBITS
(a) Financial Statements of Business Acquired
Abeona’s audited financial statements
for December 31, 2014 and 2013 are filed within this Form 8-K/A as Exhibit 99.1 and incorporated herein by reference.
Abeona’s unaudited financial
statements for March 31, 2015 and 2014 are filed within this Form 8-K/A as Exhibit 99.2 and incorporated herein by
reference.
(b) Pro Forma Financial Information
The unaudited pro forma condensed combined
financial statements with respect to PlasmaTech’s acquisition of Abeona by which Abeona became a wholly owned subsidiary
of PlasmaTech, are filed with this Form 8-K/A as Exhibit 99.3 and incorporated herein by reference and are based upon the historical
condensed consolidated financial statements and notes thereto (as applicable) of PlasmaTech and Abeona.
As previously disclosed, on May 15, 2015,
we closed our acquisition of Abeona and will issue an aggregate of 3,979,761 shares of PlasmaTech’s common stock to the members
of Abeona. In addition, there may be up to an additional $9 million in performance milestones payable to members of Abeona, in
common stock or cash, at PlasmaTech’s option.
The pro forma adjustments are based upon
available information and certain assumptions that PlasmaTech believes are reasonable under the circumstances.
These unaudited pro forma condensed combined
financial statements should be read in conjunction with the historical consolidated financial statements and related notes contained
in the annual, quarterly and other reports filed by PlasmaTech with the SEC and the audited consolidated financial statements of
Abeona included in this Form 8-K/A.
(d) Exhibits
Number |
|
Title |
23.1 |
|
Consent of Independent Auditors |
99.1 |
|
Audited financial statements of Abeona Therapeutics LLC for
the year ended December 31, 2014 and for the period from inception (March 29, 2013) through December 31,
2013 |
99.2 |
|
Unaudited financial statements of Abeona Therapeutics LLC for
the Three Months Ended March 31, 2015 and March 31, 2014 |
99.3 |
|
Unaudited Pro Forma Condensed Combined Balance Sheet as Of
March 31, 2015 and Pro Forma Condensed Combined Statement of Operations for the Three Months Ended March 31, 2015 and for the
Twelve Months Ended December 31, 2014 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
/s/ Stephen B. Thompson |
|
By: |
Stephen B. Thompson |
|
|
Vice President Finance |
Date: June 4, 2015
Exhibit Index
Exhibit No. |
|
Description |
|
|
|
23.1 |
|
Consent of Independent Auditors |
99.1 |
|
Audited financial statements of Abeona Therapeutics LLC for
the year ended December 31, 2014 and for the period from inception (March 29, 2013) through December 31,
2013 |
99.2 |
|
Unaudited financial statements of Abeona Therapeutics LLC for
the Three Months Ended March 31, 2015 and March 31, 2014 |
99.3 |
|
Unaudited Pro Forma Condensed Combined Balance Sheet as Of March 31, 2015 and Pro Forma
Condensed Combined Statement of Operations for the Three Months Ended March 31, 2015 and for the Twelve Months Ended December
31, 2014 |
EXHIBIT 23.1
CONSENT OF INDEPENDENT AUDITOR
Plasma Tech Biopharmaceuticals, Inc.
Dallas, Texas
We hereby consent to the incorporation
by reference in the Registration Statements on Form S-3 (File No. 333-204179) and Form S-8 (File Nos. 333-204055 and 333-189985)
of PlasmaTech Biopharmaceuticals, Inc. of our report dated May 16, 2015, relating to the financial statements of Abeona Therapeutics
LLC, which appears in this Form 8-K/A.
/s/ BDO USA. LLP
Cleveland, Ohio
June 4, 2015
EXHIBIT 99.1
|
Abeona Therapeutics LLC |
|
|
|
Financial Statements |
|
December 31, 2014 and 2013 |
The report accompanying these
financial statements was issued by BDO USA, LLP, a Delaware limited
liability partnership and the U.S. member of BDO International Limited, a UK company limited by guarantee. |
|
Abeona
Therapeutics LLC |
|
Financial Statements |
December 31, 2014 and 2013 |
Abeona
Therapeutics LLC |
|
Contents |
Independent Auditor’s Report |
3-4 |
|
|
Financial Statements |
|
|
|
Balance Sheets |
6 |
|
|
Statements of Operations |
7 |
|
|
Statements of Changes in Members’ Equity |
8 |
|
|
Statements of Cash Flows |
9 |
|
|
Notes to Financial Statements |
10-14 |
|
Tel: 440-248-8787 |
32125 Solon Road |
Fax: 440-248-0841 |
Cleveland, OH 44139 |
www.bdo.com |
|
Independent Auditor’s Report
To the Members
Abeona Therapeutics LLC
Cleveland, Ohio
We have audited the accompanying financial
statements of Abeona Therapeutics LLC which comprise the balance sheets as of December 31, 2014 and 2013, and the related statements
of operations and changes in members’ equity and cash flows for the year ended December 31, 2014 and for the period from
inception (March 29, 2013) through December 31, 2013, and the related notes to the financial statements.
Management’s Responsibility for the Financial Statements
Management is responsible for the preparation
and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States
of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair
presentation of financial statements that are free from material misstatement, whether due to fraud or error.
Auditor’s Responsibility
Our responsibility is to express an opinion
on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted
in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about
whether the financial statements are free from material misstatement.
An audit involves performing procedures
to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor’s
judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.
In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation and fair presentation
of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose
of expressing an opinion on the effectiveness of the entity’s internal control. Accordingly, we express no such opinion.
An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting
estimates made by management, as well as evaluating the overall presentation of the financial statements.
We believe that the audit evidence we have obtained is sufficient
and appropriate to provide a basis for our audit opinion.
BDO USA, LLP, a Delaware limited liability
partnership, is the U.S. member of BDO International Limited, a UK company limited by guarantee, and forms part of the international
BDO network of independent member firms.
BDO is the brand name for the BDO network and
for each of the BDO Member Firms.
Opinion
In
our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Abeona
Therapeutics LLC as of December 31, 2014 and 2013, and the results of its operations and its cash flows for the year ended December
31, 2014 and for the period from inception (March 29, 2013) through December 31, 2013 in accordance with accounting principles
generally accepted in the United States of America.
May
16, 2015
Abeona
Therapeutics LLC |
|
Balance Sheets |
December 31, | |
2014 | | |
2013 | |
| |
| | |
| |
Assets | |
| | | |
| | |
| |
| | | |
| | |
Current Assets | |
| | | |
| | |
Cash | |
$ | 3,993,390 | | |
$ | 625,413 | |
Prepaid expenses | |
| 30,172 | | |
| 15,264 | |
| |
| | | |
| | |
| |
| 4,023,562 | | |
| 640,677 | |
| |
| | | |
| | |
Property and Equipment, net | |
| 56,587 | | |
| - | |
| |
| | | |
| | |
Other Assets | |
| | | |
| | |
License rights, net | |
| 251,070 | | |
| 89,250 | |
Deposits | |
| 1,061 | | |
| - | |
| |
| | | |
| | |
Total Assets | |
$ | 4,332,280 | | |
$ | 729,927 | |
| |
| | | |
| | |
Liabilities and Members' Equity | |
| | | |
| | |
| |
| | | |
| | |
Current Liabilities | |
| | | |
| | |
Accounts payable | |
| 28,414 | | |
| - | |
Accrued salaries and other expenses | |
| 20,978 | | |
| 20,547 | |
| |
| | | |
| | |
Total Liabilities | |
| 49,392 | | |
| 20,547 | |
| |
| | | |
| | |
Members' Equity | |
| 4,282,888 | | |
| 709,380 | |
| |
| | | |
| | |
Total Liabilities and Members' Equity | |
$ | 4,332,280 | | |
$ | 729,927 | |
See accompanying notes to financial statements.
Abeona Therapeutics
LLC |
|
Statements of Operations |
| |
| | |
Period from March 29, | |
| |
Year ended | | |
2013 through | |
| |
December 31, 2014 | | |
December 31, 2013 | |
| |
| | |
| |
Research and Development Costs | |
$ | 27,986 | | |
$ | - | |
| |
| | | |
| | |
General and Administrative Expenses | |
| 407,959 | | |
| 139,406 | |
| |
| | | |
| | |
Operating Loss | |
| 435,945 | | |
| 139,406 | |
| |
| | | |
| | |
Other Income | |
| (1,953 | ) | |
| - | |
| |
| | | |
| | |
Net Loss | |
$ | 433,992 | | |
$ | 139,406 | |
See accompanying notes to financial statements.
Abeona
Therapeutics LLC |
|
Statements of Changes in Members' Equity |
| |
Class A Units | | |
Class B Units | | |
Class C Units | | |
Accumulated | | |
| |
| |
Units | | |
Dollars | | |
Units | | |
Dollars | | |
Units | | |
Dollars | | |
Deficit | | |
Total | |
| |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
Balance, March 29, 2013 | |
| - | | |
$ | - | | |
| - | | |
$ | - | | |
| - | | |
$ | - | | |
$ | - | | |
$ | - | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Issuance of membership units | |
| 27,405 | | |
| 755,000 | | |
| - | | |
| - | | |
| 54,595 | | |
| 3,200 | | |
| - | | |
| 758,200 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Issuance of membership units in exchange for license rights | |
| - | | |
| - | | |
| 8,000 | | |
| 90,000 | | |
| - | | |
| - | | |
| - | | |
| 90,000 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Issuance of membership units to founders for services | |
| | | |
| | | |
| | | |
| | | |
| 10,000 | | |
| 586 | | |
| - | | |
| 586 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Net Loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (139,406 | ) | |
| (139,406 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance, December 31, 2013 | |
| 27,405 | | |
| 755,000 | | |
| 8,000 | | |
| 90,000 | | |
| 64,595 | | |
| 3,786 | | |
| (139,406 | ) | |
| 709,380 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Issuance of membership units | |
| 76,750 | | |
| 3,837,500 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 3,837,500 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Issuance of membership units in exchange for license rights | |
| - | | |
| - | | |
| 6,675 | | |
| 170,000 | | |
| - | | |
| - | | |
| - | | |
| 170,000 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Net Loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (433,992 | ) | |
| (433,992 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance, December 31, 2014 | |
| 104,155 | | |
$ | 4,592,500 | | |
| 14,675 | | |
$ | 260,000 | | |
| 64,595 | | |
$ | 3,786 | | |
$ | (573,398 | ) | |
$ | 4,282,888 | |
See accompanying notes to financial statements.
Abeona Therapeutics
LLC |
|
Statements of Cash Flows |
| |
| | |
Period from March 29, | |
| |
Year ended | | |
2013 through | |
| |
December 31, 2014 | | |
December 31, 2013 | |
| |
| | |
| |
Operativing Activities | |
| | | |
| | |
Net loss | |
$ | (433,992 | ) | |
$ | (139,406 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
| | | |
| | |
Depreciation expense | |
| 3,129 | | |
| - | |
Amortization of license rights | |
| 8,180 | | |
| 750 | |
Memberhip units issued in exchange for services | |
| - | | |
| 586 | |
Increase in: | |
| | | |
| | |
Prepaid expenses and other | |
| (15,969 | ) | |
| (15,264 | ) |
Increase in: | |
| | | |
| | |
Accounts payable | |
| 28,414 | | |
| - | |
Accrued salaries and other expenses | |
| 431 | | |
| 20,547 | |
| |
| | | |
| | |
Net cash for operating activities | |
| (409,807 | ) | |
| (132,787 | ) |
| |
| | | |
| | |
Investing Activities | |
| | | |
| | |
Purchases of property and equipment | |
| (59,716 | ) | |
| - | |
| |
| | | |
| | |
Net cash for investing activities | |
| (59,716 | ) | |
| - | |
| |
| | | |
| | |
Financing Activities | |
| | | |
| | |
Proceeds from sale of units | |
| 3,837,500 | | |
| 758,200 | |
| |
| | | |
| | |
Net cash from financing activities | |
| 3,837,500 | | |
| 758,200 | |
| |
| | | |
| | |
Net change in cash | |
| 3,367,977 | | |
| 625,413 | |
| |
| | | |
| | |
Cash, beginning of year | |
| 625,413 | | |
| - | |
| |
| | | |
| | |
Cash, end of year | |
$ | 3,993,390 | | |
$ | 625,413 | |
Supplemental disclosure of non-cash investing and financing
activity:
During 2014, the Company issued 6,675 Class B units
valued at $170,000 under terms of the license agreement disclosed in Note D.
During 2013, the Company issued 8,000 Class B units
valued $90,000 under terms of the license agreement disclosed in Note D.
During 2013, the Company issued 10,000 Class C units
valued at $586 to two founders.
See accompanying notes to financial statements.
Abeona
Therapeutics LLC |
|
Notes to Financial Statements |
NOTE A - Summary of significant accounting policies
Background and nature of operations
Abeona Therapeutics LLC (the Company), an Ohio limited liability
company, is engaged in the development and commercialization of therapies for patients with lysosomal storage diseases.
The Company began operations on March 29,
2013 and its operations consist primarily of research and development expenditures, and revenues from planned principal operations
have not yet been realized. The Company relies on the sale of membership interests for funding of operations.
The Company has incurred losses from operations
since inception and has an accumulated deficit of $573,398 as of December 31, 2014. The Company anticipates incurring additional
losses until such time, if ever, that it can generate significant revenues from product candidates currently in development.
Future success of operations is subject
to several technical hurdles and risk factors, including satisfactory product development, timely initiation and completion of
clinical trials, regulatory approval and market acceptance of the Company’s products and the Company’s continued ability
to obtain future funding.
Property and equipment
Property and equipment are stated at cost
less accumulated depreciation. Maintenance and repairs are charged to operations as incurred. Depreciation is based on the straight-line
method over the estimated useful lives of the related assets which range from 2 to 5 years.
Intangible assets license rights
License rights are being amortized through the maturity date
of the licensing agreement. (See Note D).
Long-lived assets
The Company reviews its long-lived assets
for impairment whenever events or circumstances indicate that are carrying amount of an asset may not be recoverable in accordance
with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 360, Impairment or Disposal of Long-Lived
Assets.
Research and development costs
All research and development costs are charged to expense as
incurred.
Abeona
Therapeutics LLC |
|
Notes to Financial Statements |
NOTE A - Summary of significant accounting policies, continued
Income taxes
The Company, with the consent of its members,
was formed as a limited liability company. The operating agreement, construed under Ohio laws, states that the Company will be
treated as a partnership for federal and state income tax purposes. In lieu of paying taxes at the company level, the members of
a limited liability company are taxed on their proportionate share of the Company's taxable income. Therefore, no provision or
liability for federal or state income taxes has been included in these financial statements.
The Company follows the accounting guidance
for uncertainty in income taxes using the provisions of Accounting Standards Codification (ASC) 740, Income Taxes. Using
that guidance, tax positions initially need to be recognized in the financial statements when it is more likely than not the position
will be sustained upon examination by the tax authorities.
As of December 31, 2014 and 2013, the Company
had no uncertain tax positions that qualify for either recognition or disclosure in the financial statements. It is the Company’s
policy to include any penalties and interest related to income taxes in its general and administrative expenses, however,
the Company has no penalties or interest related to income taxes for the year ended December 31, 2014 and the period from March
29, 2013 through December 31, 2013, respectively. The earliest year that the Company is subject to examination is the period ended
December 31, 2013.
Concentrations of credit risk
Financial instruments that potentially
subject the Company to concentrations of credit risk consist primarily of cash. The Company places its temporary cash investments
with financial institutions which are insured up to FDIC limits. The Company has never experienced any losses related to their
balances.
Use of estimates
The preparation of financial statements
in conformity with accounting principles generally accepted in the United States of America requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of significant assets and liabilities
at the date of the financial statements, and reported amounts of expenses during the reporting period. Actual results could differ
from those estimates.
Recent accounting pronouncement
During 2014, the Company early adopted
Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements,
Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation, which eliminated the definition of a
development stage entity and certain previously required incremental financial reporting disclosures.
Abeona
Therapeutics LLC |
|
Notes to Financial Statements |
NOTE A - Summary of significant accounting policies, continued
Evaluation of subsequent events
The Company has evaluated subsequent events
through May 16, 2015, which is the date the financial statements were available to be issued, and has determined that there were
no subsequent events that have occurred through that date that have not already been reflected in the financial statements and/or
disclosed in the notes.
NOTE B - Property and equipment
Property and equipment consisted of the following at:
December 31, | |
2014 | | |
2013 | |
Lab equipment | |
$ | 55,000 | | |
$ | - | |
Computer equipment | |
| 4,716 | | |
| - | |
| |
| 59,716 | | |
| - | |
Accumulated depreciation | |
| (3,129 | ) | |
| - | |
Property and equipment, net | |
$ | 56,587 | | |
$ | - | |
Depreciation expense for the year ended December 31, 2014 and
for the period from inception (March 29, 2013) through December 31, 2013 was $3,129 and -0-, respectively.
NOTE C - Members’ equity
The interests of the Company are divided
into Class A, Class B, Class C and Class D Units. Only those members holding Class A Units and Class C Units are entitled to vote
on certain governance issues pertaining to the Company’s operations. Class D units will generally be issued pursuant to and
subject to conditions and restrictions of the Company’s equity plan, once adopted. See Note D regarding the Class B Units.
The holders of Class A Units are entitled
to receive preferred returns on a cumulative basis at a rate of 5% per annum on the daily balance of the Member’s Net Capital
Contribution, as defined by the operating agreement. As of December 31, 2014 and 2013, the Company has cumulative preferred returns
totaling approximately $111,000 and $3,500, respectively.
Subsequent to December 31, 2014, the Company issued an additional
6,000 Class A Units for $300,000 and 525 Class B Units under the terms of the licensing agreement (see Note D).
Abeona
Therapeutics LLC |
|
Notes to Financial Statements |
NOTE D - Technology license agreement
The Company is party to an exclusive
license agreement with a hospital, which owns the Class B units, dated November 8, 2013, that grants an exclusive,
non-transferable license to certain licensed patented technology of the hospital. The agreement allows the Company to
sublicense the technology upon written approval by the hospital. The agreement will end upon the earliest of (a) last to
expire valid claim of licensed patents, unless terminated earlier within the terms of the agreement or (b) twenty years after
the effective date. Additionally, the Company must achieve certain development milestones by specified dates. The license
agreement may be terminated by the hospital if the Company fails to meet each development milestone.
Under the terms of the license agreement,
until the Company has received aggregate proceeds of not less than $5,000,000 from (a) sales of membership Units together with
(b) the receipt of funds to support Company operations, the Company shall issue additional Class B Units to the Class B Unitholder
such that the Class B Unitholder holds an 8% membership interest of the Company. As of December 31, 2014 and 2013, under the terms
of the license agreement, the Company has issued 14,675 and 8,000 Class B Units, respectively.
The fair value of the Class B Units at
the date of issuance of $170,000 and $90,000 at December 31, 2014 and 2013, respectively, was recorded as license rights and is
being amortized through the maturity date of the licensing agreement. Unamortized license rights were $251,070 and $89,250 at December
31, 2014 and 2013, respectively. Amortization for the year ended December 31, 2014 and for the period from inception (March 29,
2013) through December 31, 2013 was $8,180 and $750, respectively. Future annual amortization expense will be approximately $13,300
for 2015 through 2019.
If the license agreement, noted above,
is terminated by the Company due to breach of any provision of the agreement, the Company has the right and option to purchase
the entire Class B Units within six months after the license termination date at a price commensurate of the current value, as
defined by the operating agreement.
If the license agreement, noted above,
is terminated by the Company for convenience at any time after the second anniversary or by giving written notice to the Class
B Unitholder at least six months prior to the effective termination date or by the Class B Unitholder due to breach of any provision
of the agreement or due to legal action by part of the Company, the Class B Unitholder has the right and option to cause the Company
to purchase the entire membership interests of the Class B Unitholder within six months after the license termination date at a
price commensurate of the current value, as defined by the operating agreement.
In connection with the license agreement,
the Company is required to pay an annual, non-creditable and non-refundable license maintenance fee of $15,000 the first year,
$20,000 the second year, $25,000 for years three and four, and then $30,000 for years five and beyond. License fee expense for
the years ended December 31, 2014 and 2013 was $15,000 and -0-, respectively and is included in the general and administrative
expenses on the Statements of Operations.
Abeona
Therapeutics LLC |
|
Notes to Financial Statements |
NOTE D - Technology license agreement, continued
The license agreement requires non-creditable, non-refundable
royalty payments equal to 2.5% of net sales of the licensed product sold by the Company.
The license agreement requires the Company
to pay four product development milestone payments totaling $715,000 beginning with a $15,000 payment due upon the commencement
of Phase I clinical trials, which are estimated to begin in 2015.
Under the terms of the license agreement the Company reimburses
the hospital for patent costs associated with the licensed patents.
NOTE E - Operating lease
The Company occupies office and lab space
under an operating lease. The total rent expense amounted to $6,691 and $-0- in 2014 and 2013, respectively. Future minimum lease
payments for operating leases having an initial or remaining term in excess of one year at December 31, 2014 are as follows:
December 31, 2014 | |
| |
2015 | |
$ | 23,171 | |
2016 | |
| 23,711 | |
2017 | |
| 1,980 | |
| |
$ | 48,862 | |
NOTE F - Subsequent event
On May 5, 2015, the Company entered into
an Agreement and Plan of Merger with Plasmatech Biopharmaceutical, Inc., “Plasmatech”, a company focused on gene and
cell therapy for severe and life-threatening diseases. Plasmatech, headquartered in Dallas, TX, is a public company traded on the
NASDAQ Global Market. Under terms of the agreement, upon closing of the transaction, the Company will become a wholly owned subsidiary
of Plasmatech. Members of the Company will receive 3,979,761 shares of common stock of Plasmatech and Plasmatech will become the
sole member of the Company. Those shares will be allocated in accordance with the Company’s operating agreement, including
payment of preferred returns. The members of the Company may also receive additional consideration totaling $9,000,000 in the form
of cash, stock in Plasmatech, or a combination of both, if certain milestones enumerated in the agreement are achieved within the
time periods defined.
EXHIBIT
99.2
Abeona
Therapeutics LLC
Balance Sheets
(unaudited)
| |
March 31, 2015 | | |
December 31, 2014 | |
| |
| | |
| |
ASSETS | |
| | | |
| | |
Cash | |
$ | 4,026,000 | | |
$ | 3,993,000 | |
Prepaid expenses | |
| 24,000 | | |
| 30,000 | |
Total current assets | |
| 4,050,000 | | |
| 4,023,000 | |
| |
| | | |
| | |
Property and Equipment, net | |
| 53,000 | | |
| 57,000 | |
| |
| | | |
| | |
Other Assets | |
| | | |
| | |
License rights, net | |
| 261,000 | | |
| 251,000 | |
Deposits | |
| 1,000 | | |
| 1,000 | |
| |
| | | |
| | |
Total assets | |
$ | 4,365,000 | | |
$ | 4,332,000 | |
| |
| | | |
| | |
LIABILITIES AND MEMBERS’ EQUITY | |
| | | |
| | |
Current liabilities | |
| | | |
| | |
Accounts payable | |
$ | 135,000 | | |
$ | 28,000 | |
Accrued salaries and other expenses | |
| 49,000 | | |
| 17,000 | |
Unearned revenue | |
| 1,000 | | |
| 4,000 | |
Total liabilities | |
| 185,000 | | |
| 49,000 | |
| |
| | | |
| | |
Members’ equity | |
| | | |
| | |
Contributed capital | |
| 5,120,000 | | |
| 4,857,000 | |
Accumulated deficit | |
| (990,000 | ) | |
| (574,000) | |
| |
| 4,180,000 | | |
| 4,283,000 | |
| |
| | | |
| | |
Total liabilities and members’ equity | |
$ | 4,365,000 | | |
$ | 4,332,000 | |
See accompanying notes to financial statements.
Abeona
Therapeutics LLC
Statement of Operations
(unaudited)
| |
Three Months
ended | | |
Three Months
ended | |
| |
March 31, 2015 | | |
March 31, 2014 | |
| |
| | |
| |
Research and development costs | |
$ | 279,000 | | |
$ | - | |
General and administrative expenses | |
| 133,000 | | |
| 72,000 | |
Depreciation and amortization | |
| 7,000 | | |
| 1,000 | |
Operating loss | |
| 419,000 | | |
| 73,000 | |
| |
| | | |
| | |
Other income | |
| (3,000 | ) | |
| - | |
| |
| | | |
| | |
Net loss | |
$ | 416,000 | | |
$ | 73,000 | |
See accompanying notes to financial statements.
Abeona
Therapeutics LLC
Statements of Cash Flows
(unaudited)
| |
Three Months
ended | | |
Three Months
ended | |
| |
March 31, 2015 | | |
March 31, 2014 | |
| |
| | |
| |
Cash flows from operating activities: | |
| | | |
| | |
Net loss | |
$ | (416,000 | ) | |
$ | (73,000 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
| | | |
| | |
Depreciation expense | |
| 4,000 | | |
| - | |
Amortization of licensing rights | |
| 3,000 | | |
| 1,000 | |
Decrease (increase) in prepaid expenses | |
| 6,000 | | |
| (2,000 | ) |
Increase in accounts payable | |
| 107,000 | | |
| - | |
Increase in accrued salaries and other expenses | |
| 32,000 | | |
| 4,000 | |
Decrease in unearned
revenue | |
| (3,000 | ) | |
| - | |
Net cash used in operating activities | |
| (267,000 | ) | |
| (70,000 | ) |
| |
| | | |
| | |
Cash flows from investing activities: | |
| | | |
| | |
Purchases of property and equipment | |
| - | | |
| (2,000 | ) |
Net cash used in investing activities | |
| - | | |
| (2,000 | ) |
| |
| | | |
| | |
Cash flows from financing activities: | |
| | | |
| | |
Proceeds from sale of units | |
| 300,000 | | |
| - | |
Net cash used in financing activities | |
| 300,000 | | |
| - | |
| |
| | | |
| | |
Net increase (decrease) in cash and cash
equivalents | |
| 33,000 | | |
| (72,000 | ) |
Cash at beginning of period | |
| 3,993,000 | | |
| 625,000 | |
Cash at end of period | |
$ | 4,026,000 | | |
$ | 553,000 | |
See accompanying notes to financial statements.
Abeona
Therapeutics LLC
Notes to Financial Statements
(unaudited)
Abeona Therapeutics LLC (the Company),
an Ohio limited liability company, is engaged in the development and commercialization of therapies for patients with lysosomal
storage diseases.
The Company began operations on March 29,
2013 and its operations consist primarily of research and development expenditures, and revenues from planned principal operations
have not yet been realized. The Company relies on the sale of membership interests for funding of operations.
The Company has incurred losses from operations
since inception and has an accumulated deficit of $990,000 as of March 31, 2015. The Company anticipates incurring additional losses
until such time, if ever, that it can generate significant revenues from product candidates currently in development.
Future success of operations is subject
to several technical hurdles and risk factors, including satisfactory product development, timely initiation and completion of
clinical trials, regulatory approval and market acceptance of the Company’s products and the Company’s continued ability
to obtain future funding.
| (1) | Interim Financial Statements |
The balance sheet as of March 31, 2015,
the statements of operations for the three months ended March 31, 2015 and 2014, and the statements of cash flows for the three
months ended March 31, 2015 and 2014, were prepared by management without audit. In the opinion of management, all adjustments,
consisting only of normal recurring adjustments, except as otherwise disclosed, necessary for the fair presentation of the financial
position, results of operations, and changes in financial position for such periods, have been made.
Certain information and footnote disclosures
normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States
of America have been condensed or omitted. It is suggested that these interim financial statements be read in conjunction with
the financial statements and notes thereto for the year ended December 31, 2014. The results of operations for the period ended
March 31, 2015 are not necessarily indicative of the operating results which may be expected for a full year.
Abeona
Therapeutics LLC
Notes to Financial Statements
(unaudited)
| (2) | Technology license agreement |
The Company is party to an exclusive license
agreement with a hospital, which owns the Class B units, dated November 8, 2013, that grants an exclusive, non-transferable license
to certain licensed patented technology of the hospital. The agreement allows the Company to sublicense the technology upon written
approval by the hospital. The agreement will end upon the earliest of (a) last to expire valid claim of licensed patents, unless
terminated earlier within the terms of the agreement or (b) twenty years after the effective date. Additionally, the Company must
achieve certain development milestones by specified dates. The license agreement may be terminated by the hospital if the Company
fails to meet each development milestone.
Under the terms of the license agreement,
until the Company has received aggregate proceeds of not less than $5,000,000 from (a) sales of membership Units together with
(b) the receipt of funds to support Company operations, the Company shall issue additional Class B Units to the Class B Unitholder
such that the Class B Unitholder holds an 8% membership interest of the Company. As of March 31, 2015 and 2014, under the terms
of the license agreement, the Company has issued 15,200 and 8,000 Class B Units, respectively.
The fair value of the Class B
Units at the date of issuance of $273,000 and $260,000 at March 31, 2015 and December 31, 2014, respectively, was recorded as
license rights and is being amortized through the maturity date of the licensing agreement. Unamortized license rights were
$261,000 and $251,000 at March 31, 2015 and December 31, 2014, respectively. Amortization for the period ended March 31, 2015
and for the period ended March 31, 2014 was $3,000 and $1,000, respectively. Future annual amortization expense will
be approximately $14,000 for 2015 through 2019.
If the license agreement, noted above,
is terminated by the Company due to breach of any provision of the agreement, the Company has the right and option to purchase
the entire Class B Units within six months after the license termination date at a price commensurate of the current value, as
defined by the operating agreement.
If the license agreement, noted above,
is terminated by the Company for convenience at any time after the second anniversary or by giving written notice to the Class
B Unitholder at least six months prior to the effective termination date or by the Class B Unitholder due to breach of any provision
of the agreement or due to legal action by part of the Company, the Class B Unitholder has the right and option to cause the Company
to purchase the entire membership interests of the Class B Unitholder within six months after the license termination date at a
price commensurate of the current value, as defined by the operating agreement.
In connection with the license agreement,
the Company is required to pay an annual, non-creditable and non-refundable license maintenance fee of $15,000 the first year,
$20,000 the second year, $25,000 for years three and four, and then $30,000 for years five and beyond.
The license agreement requires non-creditable,
non-refundable royalty payments equal to 2.5% of net sales of the licensed product sold by the Company.
The license agreement requires the Company
to pay four product development milestone payments totaling $715,000 beginning with a $15,000 payment due upon the commencement
of Phase I clinical trials, which are estimated to begin in the third or fourth quarter of 2015.
Abeona
Therapeutics LLC
Notes to Financial Statements
(unaudited)
Under the terms of the license agreement
the Company reimburses the hospital for patent costs associated with the licensed patents.
For the three months ended March
31, 2015, the Company issued an additional 6,000 Class A Units for $300,000 and 525 Class B Units for $13,000 under the terms
of the licensing agreement.
On May 15, 2015, the Company closed an
Agreement and Plan of Merger with PlasmaTech Biopharmaceuticals, Inc., “PlasmaTech”, a company focused on gene and
cell therapy for severe and life-threatening diseases. PlasmaTech, headquartered in Dallas, TX, is a public company traded on the
NASDAQ Global Market. Under terms of the agreement the Company become a wholly owned subsidiary of PlasmaTech on May 15, 2015.
Members of the Company received 3,979,761 shares of common stock of PlasmaTech and PlasmaTech became the sole member of the Company.
Those shares are allocated in accordance with the Company’s operating agreement, including payment of preferred returns.
The members of the Company may also receive additional consideration totaling $9,000,000 in the form of cash, stock in PlasmaTech,
or a combination of both, if certain milestones enumerated in the agreement are achieved within the time periods defined.
EXHIBIT 99.3
PLASMATECH BIOPHARMACEUTICALS, INC,
UNAUDITED PRO FORMA CONDENSED
COMBINED FINANCIAL STATEMENTS
The following unaudited pro forma condensed
combined financial statements apply to the merger between Abeona Therapeutics LLC (“Abeona”) and PlasmaTech Biopharmaceuticals,
Inc. (“PlasmaTech”), by which Abeona became a wholly owned subsidiary of PlasmaTech, and are based upon the historical
condensed consolidated financial statements and notes thereto (as applicable) of PlasmaTech and Abeona.
The unaudited pro forma
condensed combined balance sheet at March 31, 2015 gives pro forma effect to the merger as if the merger had been completed
on March 31, 2015 and combines PlasmaTech’s unaudited combined balance sheet and Abeona’s unaudited balance sheet
as of March 31, 2015.
The unaudited pro forma condensed
combined statement of operations for the three months ended March 31, 2015 gives pro forma effect to the merger as if it had
been completed on January 1, 2014 and combines PlasmaTech’s unaudited consolidated statements and
Abeona’s unaudited statements of operations for the three months ended March 31, 2015.
The unaudited pro forma condensed
combined statement of operations for the twelve months ended December 31, 2014 gives pro forma effect to the merger as if it
had been completed on January 1, 2014 and combines PlasmaTech’s audited consolidated statements of operations and
Abeona’s audited statements of operations for the year ended December 31, 2014.
As previously disclosed, on May 15, 2015,
we closed our acquisition of Abeona and will issue an aggregate of 3,979,761 shares of PlasmaTech’s common stock to the members
of Abeona. In addition, there may be up to an additional $9 million in performance milestones payable to members of Abeona, in
common stock or cash, at PlasmaTech’s option.
The pro forma adjustments are based upon
available information and certain assumptions that PlasmaTech believes are reasonable under the circumstances and are based upon
our preliminary purchase price allocation.
These unaudited pro forma condensed combined
financial statements should be read in conjunction with the historical consolidated financial statements and related notes contained
in the annual, quarterly and other reports filed by PlasmaTech with the SEC and the audited consolidated financial statements of
Abeona included in this Form 8-K/A.
Basis of Presentation
The unaudited pro forma condensed combined
financial information has been derived from the historical financial information of the PlasmaTech and Abeona and was prepared
using the acquisition method of accounting in accordance with the Financial Accounting Standards Board’s Accounting Standards
Codification (“ASC”) 805, Business Combinations, and uses the fair value concepts defined in ASC 820, Fair Value Measurements
and Disclosures. ASC 805 requires, among other things, that all assets acquired and liabilities assumed be recognized at their
fair values as of the purchase date. In addition ASC 805 establishes that the consideration transferred be measured at the closing
date of the purchase at the then-current market price. Under ASC 805, acquisition-related transaction costs (e.g., advisory, legal,
valuation, other professional fees) and certain acquisition-related restructuring charges impacting the target company are not
included as a component of consideration transferred but are accounted for as expenses in the periods in which the costs are incurred.
The pro forma adjustments are preliminary
and have been made solely for the purpose of providing unaudited pro forma condensed combined financial information. The Company
anticipates that the values assigned to the assets acquired and liabilities assumed will be finalized during the measurement period
following the May 15, 2015 closing date.
Pro Forma Condensed Combined Balance
Sheet
As of March 31, 2015
(Unaudited)
Historical
| |
PlasmaTech | | |
Abeona | | |
Pro Forma Adjustments | | |
Pro Forma Combined | |
ASSETS | |
| | | |
| | | |
| | | |
| | |
Current assets | |
| | | |
| | | |
| | | |
| | |
Cash and cash equivalents | |
$ | 7,948,000 | | |
$ | 4,026,000 | | |
| | | |
$ | 11,974,000 | |
Receivables | |
| 144,000 | | |
| - | | |
| | | |
| 144,000 | |
Prepaid expenses and other current expenses | |
| 98,000 | | |
| 24,000 | | |
| | | |
| 122,000 | |
Total current assets | |
| 8,190,000 | | |
| 4,050,000 | | |
| | | |
| 12,240,000 | |
| |
| | | |
| | | |
| | | |
| | |
Property and equipment, net | |
| 11,000 | | |
| 53,000 | | |
| | | |
| 64,000 | |
Licensed technology, net | |
| 4,875,000 | | |
| 261,000 | | |
| 2,156,000 | (a) | |
| 7,031,000 | |
| |
| | | |
| | | |
| (261,000 | )(a) | |
| | |
Goodwill | |
| - | | |
| - | | |
| 32,172,000 | (a) | |
| 32,173,000 | |
Other assets | |
| 41,000 | | |
| 1,000 | | |
| | | |
| 42,000 | |
Total assets | |
$ | 13,117,000 | | |
$ | 4,365,000 | | |
| | | |
$ | 51,550,000 | |
| |
| | | |
| | | |
| | | |
| | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | |
| | | |
| | | |
| | | |
| | |
Current liabilities | |
| | | |
| | | |
| | | |
| | |
Accounts payable and accrued expenses | |
$ | 638,000 | | |
$ | 184,000 | | |
| 375,000 | (c) | |
$ | 1,197,000 | |
Short-term milestone payment liabilities | |
| - | | |
| - | | |
| 5,694,000 | (d) | |
| 5,694,000 | |
Current portion of deferred revenue | |
| 602,000 | | |
| 1,000 | | |
| | | |
| 603,000 | |
Total current liabilities | |
| 1,240,000 | | |
| 185,000 | | |
| | | |
| 7,494,000 | |
| |
| | | |
| | | |
| | | |
| | |
Long-term milestone payment liability | |
| - | | |
| - | | |
| 795,000 | (d) | |
| 795,000 | |
Payable due Licensor | |
| 4,000,000 | | |
| - | | |
| | | |
| 4,000,000 | |
Long-term debt deferred revenue | |
| 4,718,000 | | |
| - | | |
| | | |
| 4,718,000 | |
Total liabilities | |
| 9,958,000 | | |
| 185,000 | | |
| | | |
| 17,007,000 | |
| |
| | | |
| | | |
| | | |
| | |
Stockholders’ equity | |
| | | |
| | | |
| | | |
| | |
Common stock | |
| 200,000 | | |
| - | | |
| 40,000 | (a) | |
| 240,000 | |
Additional paid-in capital | |
| 301,033,000 | | |
| - | | |
| 38,207,000 | (a) | |
| 332,752,000 | |
| |
| | | |
| | | |
| (3,919,000 | )(a) | |
| | |
| |
| | | |
| | | |
| (261,000 | )(a) | |
| | |
| |
| | | |
| | | |
| 4,180,000 | (b) | |
| | |
| |
| | | |
| | | |
| (6,489,000 | )(d) | |
| | |
Member’s equity | |
| - | | |
| 4,180,000 | | |
| (4,180,000 | )(b) | |
| - | |
Accumulated deficit | |
| (298,074,000 | ) | |
| | | |
| (375,000 | )(c) | |
| (298,449,000 | ) |
Total stockholders’ equity | |
| 3,159,000 | | |
| 4,180,000 | | |
| | | |
| 34,543,000 | |
Total liabilities and stockholders’ equity | |
$ | 13,117,000 | | |
$ | 4,365,000 | | |
| | | |
$ | 51,550,000 | |
See accompanying Notes to Pro Forma Condensed
Combined Balance Sheet
Notes to Pro Forma Condensed Combined
Balance Sheet
Note 1:
The above statement gives effect to the following pro forma adjustments necessary to reflect the merger of PlasmaTech and Abeona,
as if the transaction had occurred March 31, 2015.
| a) | To record the exchange, for accounting purposes, by Abeona
members of their units for 3,979,761 shares of PlasmaTech. The initial consideration of $31,758,000 was calculated using the PlasmaTech
stock price on date of the close, May 15, 2015 of $7.98 times the number of PlasmaTech shares (3,979,761) issued to Abeona members. |
There is a contingent valuation
on three milestones. Per the merger agreement with Abeona each milestone would consist of either cash, our stock or a combination
of both, at PlasmaTech’s election, equivalent to a stated dollar amount. The fair value of the probability of achieving
all three milestones is estimated at $6,489,000.
The following
preliminary purchase price allocation is based on information we have to date and is unaudited. We expect to finalize our purchase
price allocation once all information has been obtained.
Total purchase price | |
| | |
Initial consideration | |
$ | 31,758,000 | |
Contingent consideration | |
| 6,489,000 | |
Total purchase price | |
$ | 38,247,000 | |
| |
| | |
Allocation of the purchase price | |
| | |
Cash | |
$ | 4,026,000 | |
Prepaid expenses | |
| 24,000 | |
Property and equipment | |
| 53,000 | |
Other assets | |
| 1,000 | |
Accounts payable | |
| (184,000 | ) |
Unearned revenue | |
| (1,000 | ) |
Total tangible assets | |
| 3,919,000 | |
| |
| | |
Licensing agreement | |
| 2,156,000 | |
Goodwill | |
| 32,172,000 | |
Total intangible assets | |
| 34,329,000 | |
| |
| | |
Total net asset value | |
$ | 38,247,000 | |
| b) | To eliminate the Members’ Equity
of Abeona. |
| c) | To record $375,000 in merger costs. |
| d) | To record milestone liabilities. The present
value of probability of the short-term milestone liabilities for milestone #1 and #2 are $5,694,000 and long-term liability for
milestone #3 is $795,000. |
After the consummation of the transactions
described herein, PlasmaTech had 200,000,000 common shares authorized, and approximately 23,978,562 common shares were issued and
outstanding at March 31, 2015.
Pro Forma Condensed Combined Statement
of Operations
For the Three Months Ended March 31,
2015
(Unaudited)
Historical
| |
PlasmaTech | | |
Abeona | | |
Pro Forma Adjustments | | |
Pro Forma Combined | |
| |
| | | |
| | | |
| | | |
| | |
Revenues | |
$ | 258,000 | | |
$ | - | | |
| | | |
$ | 258,000 | |
| |
| | | |
| | | |
| | | |
| | |
Expenses | |
| | | |
| | | |
| | | |
| | |
Research and development | |
| 453,000 | | |
| 279,000 | | |
| | | |
| 732,000 | |
General and administrative | |
| 1,689,000 | | |
| 133,000 | | |
| (173,000 | )(b) | |
| 1,649,000 | |
Depreciation and amortization | |
| 118,000 | | |
| 7,000 | | |
| 27,000 | (a) | |
| 152,000 | |
Total expenses | |
| 2,260,000 | | |
| 419,000 | | |
| | | |
| 2,533,000 | |
| |
| | | |
| | | |
| | | |
| | |
Loss from operations | |
| (2,002,000 | ) | |
| (419,000 | ) | |
| | | |
| (2,275,000 | ) |
| |
| | | |
| | | |
| | | |
| | |
Interest and miscellaneous income | |
| 3,000 | | |
| 3,000 | | |
| | | |
| 6,000 | |
Interest and other expenses | |
| (1,000 | ) | |
| - | | |
| | | |
| (1,000 | ) |
| |
| 2,000 | | |
| 3,000 | | |
| | | |
| (5,000 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net loss allocable to common stockholders | |
$ | (2,000,000 | ) | |
$ | (416,000 | ) | |
| | | |
$ | (2,280,000 | ) |
| |
| | | |
| | | |
| | | |
| | |
Basic and diluted loss per common share | |
| | | |
| | | |
| | | |
| | |
Loss allocable to all common stockholders | |
$ | (0.10 | ) | |
| | | |
| | | |
$ | (0.10 | ) |
| |
| | | |
| | | |
| | | |
| | |
Weighted average basic and diluted common shares outstanding | |
| 19,983,751 | | |
| | | |
| | | |
| 23,963,512 | |
Notes to Pro Forma Condensed Combined Statement of Operations
Note 1: The above statement gives effect to the merger of PlasmaTech
and Abeona, as if the merger had occurred on January 1, 2014.
a) To record $27,000, three months amortization of the licensing
agreement for estimated change in fair value.
b) To reverse $173,000 in merger costs recorded in the
first quarter of 2015.
Note 2: The pro forma combined-weighted
average number of common outstanding shares is based on the weighted average number of shares of common stock of PlasmaTech during
the period plus those shares to be issued in conjunction with the merger. A reconciliation between PlasmaTech's historical weighted
average shares outstanding and pro forma weighted average shares outstanding and pro forma weighted average shares outstanding
is as follows:
Historical | |
| 19,983,751 | |
Abeona equivalent shares giving effect to the merger | |
| 3,979,761 | |
Total | |
| 23,963,512 | |
Pro Forma Condensed Combined Statement
of Operations
For the Twelve Months Ended December
31, 2014
(Unaudited)
Historical
| |
PlasmaTech | | |
Abeona | | |
Pro Forma Adjustments | | |
Pro Forma Combined | |
| |
| | | |
| | | |
| | | |
| | |
Revenues | |
$ | 925,000 | | |
$ | - | | |
| | | |
$ | 925,000 | |
| |
| | | |
| | | |
| | | |
| | |
Expenses | |
| | | |
| | | |
| | | |
| | |
Research and development | |
| 333,000 | | |
| 28,000 | | |
| | | |
| 361,000 | |
General and administrative | |
| 3,712,000 | | |
| 397,000 | | |
| | | |
| 4,109,000 | |
Depreciation and amortization | |
| 11,000 | | |
| 11,000 | | |
| 109,000 | (a) | |
| 131,000 | |
Total expenses | |
| 4,056,000 | | |
| 436,000 | | |
| | | |
| 4,601,000 | |
| |
| | | |
| | | |
| | | |
| | |
Loss from operations | |
| (3,131,000 | ) | |
| (436,000 | ) | |
| | | |
| (3,676,000 | ) |
| |
| | | |
| | | |
| | | |
| | |
Interest and miscellaneous income | |
| 45,000 | | |
| 2,000 | | |
| | | |
| 47,000 | |
Interest and other expenses | |
| (582,000 | ) | |
| - | | |
| | | |
| (582,000 | ) |
Loss on change in fair value of derivative preferred stock | |
| (23,110,000 | ) | |
| - | | |
| | | |
| (23,110,000 | ) |
| |
| (23,647,000 | ) | |
| 2,000 | | |
| | | |
| (23,645,000 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net loss | |
| (26,778,000 | ) | |
| (434,000 | ) | |
| | | |
| (27,321,000 | ) |
| |
| | | |
| | | |
| | | |
| | |
Less preferred stock dividends | |
| (2,875,000 | ) | |
| - | | |
| | | |
| (2,875,000 | ) |
Net loss allocable to common stockholders | |
$ | (29,653,000 | ) | |
$ | (434,000 | ) | |
| | | |
$ | (30,196,000 | ) |
| |
| | | |
| | | |
| | | |
| | |
Basic and diluted loss per common share | |
| | | |
| | | |
| | | |
| | |
Loss allocable to all common stockholders | |
$ | (15.26 | ) | |
| | | |
| | | |
$ | (5.10 | ) |
| |
| | | |
| | | |
| | | |
| | |
Weighted average basic and diluted common shares outstanding | |
| 1,942,905 | | |
| | | |
| | | |
| 5,922,666 | |
Notes to Pro Forma Condensed Combined Statement of Operations
Note 1: The above statement gives effect to the merger of PlasmaTech
and Abeona, as if the merger had occurred on January 1, 2014.
a) To record $109,000, twelve months amortization of the licensing
agreement for estimated change in fair value.
Note 2: The pro forma combined-weighted
average number of common outstanding shares is based on the weighted average number of shares of common stock of PlasmaTech during
the period plus those shares to be issued in conjunction with the merger. A reconciliation between PlasmaTech's historical weighted
average shares outstanding and pro forma weighted average shares outstanding and pro forma weighted average shares outstanding
is as follows:
Historical | |
| 1,942,905 | |
Abeona equivalent shares giving effect to the merger | |
| 3,979,761 | |
Total | |
| 5,922,666 | |
Abeona Therapeutics (NASDAQ:ABEOW)
過去 株価チャート
から 5 2024 まで 6 2024
Abeona Therapeutics (NASDAQ:ABEOW)
過去 株価チャート
から 6 2023 まで 6 2024